Andrea B. Parker

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

CNP Therapeutics, Inc. manufactures medical systems for chronic pain, depression and anxiety. The company was founded by Frank Prato and Alex Thomas on September 16, 1998 and is headquartered in Mississauga, Canada.

SOCAR Research SA provides clinical research services. It provides services in the areas which include cardiovascular and related, cachexia, hematology, hypertension, metabolic, nephrology, nutraceuticals and oncology telemedicine. The firm's technology include e-SOCDAT is an e-clinical solution which provides e-design, e-data and e-data services. It serves the biotechnology, consumer healthcare, medical device, pharmaceutical, contract research organization and academic institutions. The company was founded in 1986 and is headquartered in Nyon, Switzerland.

Toronto General Hospital provides health care service. Its programs include medical and community care, multi-organ transplant, peter munk cardiac centre, surgery and critical care. The company was founded in and is headquartered in Toronto, Canada.